Drugs / ONO-4685
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06547528 | Oct 2023 → Jan 2029 expected | non-Hodgkin lymphoma | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05332704 | Mar 2022 → Jul 2024 | psoriasis | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05079282 | Dec 2021 → Aug 2027 expected | T-cell non-Hodgkin lymphoma | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04079062 | Sep 2019 → May 2021 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-4685 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06547528 ↗ |
| Route | Intravenous | “ONO-4685 will be administered by intravenous continuous infusion” NCT04079062 ↗ |